Meta-analysis of IL-17 inhibitors in two populations of rheumatoid arthritis patients: biologic-naïve or tumor necrosis factor inhibitor inadequate responders

Secukinumab after anti-tumour necrosis factor-α therapy: a phase III study in active rheumatoid arthritis

(2018) E Dokoupilová et al.   SCANDINAVIAN JOURNAL OF RHEUMATOLOGY

Secukinumab in Active Rheumatoid Arthritis: A Phase III Randomized, Double-Blind, Active Comparator- and Placebo-Controlled Study

(2017) Francisco J. Blanco et al.   Arthritis & Rheumatology

The association of hypertension with asymptomatic cardiovascular organ damage in rheumatoid arthritis

(2016) Helga Midtbø et al.   BLOOD PRESSURE

A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis

(2016) K.A. Papp et al.   BRITISH JOURNAL OF DERMATOLOGY

Efficacy and Safety of Subcutaneous and Intravenous Loading Dose Regimens of Secukinumab in Patients with Active Rheumatoid Arthritis: Results from a Randomized Phase II Study

(2016) W. Tlustochowicz et al.   JOURNAL OF RHEUMATOLOGY

Anti-IL-17 therapy in treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials

(2016) Sumit Kunwar et al.   RHEUMATOLOGY INTERNATIONAL

Cytokines IL-17 and IL-22 in the host response to infection

(2016) Maria Valeri et al.   Pathogens and Disease

Safety and Efficacy of Open-label Subcutaneous Ixekizumab Treatment for 48 Weeks in a Phase II Study in Biologic-naive and TNF-IR Patients with Rheumatoid Arthritis

(2015) Mark C. Genovese et al.   JOURNAL OF RHEUMATOLOGY

A Study to Evaluate the Safety, Tolerability, and Efficacy of Brodalumab in Subjects with Rheumatoid Arthritis and an Inadequate Response to Methotrexate

(2015) K. Pavelka et al.   JOURNAL OF RHEUMATOLOGY

Association ofHLA-DRB1alleles with clinical responses to the anti-interleukin-17A monoclonal antibody secukinumab in active rheumatoid arthritis

(2015) Gerd R. Burmester et al.   RHEUMATOLOGY

2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

(2015) Jasvinder A. Singh et al.   ARTHRITIS CARE & RESEARCH

The Burden of Disease in Rheumatoid Arthritis

(2014) Till Uhlig et al.   PHARMACOECONOMICS

A Phase II Randomized Study of Subcutaneous Ixekizumab, an Anti-Interleukin-17 Monoclonal Antibody, in Rheumatoid Arthritis Patients Who Were Naive to Biologic Agents or Had an Inadequate Response to Tumor Necrosis Factor Inhibitors

(2014) Mark C. Genovese et al.   Arthritis & Rheumatology

A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis

(2013) David A Martin et al.   ARTHRITIS RESEARCH & THERAPY

Incomplete response of inflammatory arthritis to TNFα blockade is associated with the Th17 pathway

(2012) Saba Alzabin et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study

(2012) Mark C Genovese et al.   ANNALS OF THE RHEUMATIC DISEASES

Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients

(2011) A Jamnitski et al.   ANNALS OF THE RHEUMATIC DISEASES

The Pathogenesis of Rheumatoid Arthritis

(2011) Iain B. McInnes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Chronic Mucocutaneous Candidiasis in Humans with Inborn Errors of Interleukin-17 Immunity

(2011) A. Puel et al.   SCIENCE

Dual role of interleukin-17 in pannus growth and osteoclastogenesis in rheumatoid arthritis

(2011) Hiroshi Ito et al.   ARTHRITIS RESEARCH & THERAPY

LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study

(2010) M. C. Genovese et al.   ARTHRITIS AND RHEUMATISM

IL-17 Contributes to Angiogenesis in Rheumatoid Arthritis

(2010) S. R. Pickens et al.   JOURNAL OF IMMUNOLOGY

Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

(2010) W. Hueber et al.   Science Translational Medicine

Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis

(2009) Hui Shen et al.   ARTHRITIS AND RHEUMATISM

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

(2009) Alessandro Liberati et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial

(2009) Josef S Smolen et al.   LANCET

Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases

(2009) Sherine E Gabriel et al.   ARTHRITIS RESEARCH & THERAPY

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

(2008) P. Emery et al.   ANNALS OF THE RHEUMATIC DISEASES

Recent developments in the immunobiology of rheumatoid arthritis

(2008) Anna K Andersson et al.   ARTHRITIS RESEARCH & THERAPY

IL-17/Th17 targeting: On the road to prevent chronic destructive arthritis?

(2007) Erik Lubberts   CYTOKINE